CN103173417B - 小鼠抗人cea单克隆抗体及分泌该单克隆抗体的杂交瘤细胞株 - Google Patents
小鼠抗人cea单克隆抗体及分泌该单克隆抗体的杂交瘤细胞株 Download PDFInfo
- Publication number
- CN103173417B CN103173417B CN201310041303.3A CN201310041303A CN103173417B CN 103173417 B CN103173417 B CN 103173417B CN 201310041303 A CN201310041303 A CN 201310041303A CN 103173417 B CN103173417 B CN 103173417B
- Authority
- CN
- China
- Prior art keywords
- cea
- monoclonal antibody
- seq
- hybridoma cell
- cell strain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 210000004408 hybridoma Anatomy 0.000 title claims abstract description 27
- 102000012406 Carcinoembryonic Antigen Human genes 0.000 title abstract description 70
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 title abstract description 70
- 230000003248 secreting effect Effects 0.000 title abstract description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 6
- 238000002649 immunization Methods 0.000 claims description 9
- 230000003053 immunization Effects 0.000 claims description 8
- 230000009465 prokaryotic expression Effects 0.000 claims description 3
- 230000028327 secretion Effects 0.000 claims description 3
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 108020004414 DNA Proteins 0.000 abstract description 10
- 230000014509 gene expression Effects 0.000 abstract description 6
- 238000011160 research Methods 0.000 abstract description 5
- 238000013115 immunohistochemical detection Methods 0.000 abstract description 2
- 102000053602 DNA Human genes 0.000 abstract 5
- 238000000034 method Methods 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- 206010028980 Neoplasm Diseases 0.000 description 12
- 239000000427 antigen Substances 0.000 description 10
- 102000036639 antigens Human genes 0.000 description 10
- 108091007433 antigens Proteins 0.000 description 10
- 150000001413 amino acids Chemical group 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 208000029742 colonic neoplasm Diseases 0.000 description 8
- 206010009944 Colon cancer Diseases 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 230000036039 immunity Effects 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 238000012408 PCR amplification Methods 0.000 description 5
- 230000002494 anti-cea effect Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 201000010897 colon adenocarcinoma Diseases 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 206010003445 Ascites Diseases 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000012188 paraffin wax Substances 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 208000015634 Rectal Neoplasms Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 210000003754 fetus Anatomy 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 229930027917 kanamycin Natural products 0.000 description 3
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 3
- 229960000318 kanamycin Drugs 0.000 description 3
- 229930182823 kanamycin A Natural products 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 229960000856 protein c Drugs 0.000 description 3
- 238000003259 recombinant expression Methods 0.000 description 3
- 206010038038 rectal cancer Diseases 0.000 description 3
- 201000001275 rectum cancer Diseases 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 235000011149 sulphuric acid Nutrition 0.000 description 3
- 239000001117 sulphuric acid Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 101150045267 CEA gene Proteins 0.000 description 2
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 238000011091 antibody purification Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000007910 cell fusion Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000024835 cytogamy Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 201000005619 esophageal carcinoma Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000001744 histochemical effect Effects 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- -1 polyoxyethylene Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 208000020615 rectal carcinoma Diseases 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 201000000498 stomach carcinoma Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 241000672609 Escherichia coli BL21 Species 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- WQZGKKKJIJFFOK-PQMKYFCFSA-N alpha-D-mannose Chemical compound OC[C@H]1O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-PQMKYFCFSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 210000004953 colonic tissue Anatomy 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 210000001900 endoderm Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 208000003243 intestinal obstruction Diseases 0.000 description 1
- YDTFRJLNMPSCFM-YDALLXLXSA-M levothyroxine sodium anhydrous Chemical compound [Na+].IC1=CC(C[C@H](N)C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 YDTFRJLNMPSCFM-YDALLXLXSA-M 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 229940005654 nitrite ion Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000002706 plastid Anatomy 0.000 description 1
- 210000004910 pleural fluid Anatomy 0.000 description 1
- 208000014081 polyp of colon Diseases 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Landscapes
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310041303.3A CN103173417B (zh) | 2013-02-04 | 2013-02-04 | 小鼠抗人cea单克隆抗体及分泌该单克隆抗体的杂交瘤细胞株 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310041303.3A CN103173417B (zh) | 2013-02-04 | 2013-02-04 | 小鼠抗人cea单克隆抗体及分泌该单克隆抗体的杂交瘤细胞株 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103173417A CN103173417A (zh) | 2013-06-26 |
CN103173417B true CN103173417B (zh) | 2015-04-22 |
Family
ID=48633609
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310041303.3A Expired - Fee Related CN103173417B (zh) | 2013-02-04 | 2013-02-04 | 小鼠抗人cea单克隆抗体及分泌该单克隆抗体的杂交瘤细胞株 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103173417B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105693862B (zh) * | 2016-03-07 | 2019-06-18 | 中国人民解放军第二军医大学 | 抗融合蛋白cea576-669hsp70l1单克隆抗体4e8及其用途 |
CN105693863B (zh) * | 2016-03-07 | 2019-06-18 | 中国人民解放军第二军医大学 | 抗融合蛋白cea576-669hsp70l1单克隆抗体3c1及其用途 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1330545C (en) * | 1989-09-15 | 1994-07-05 | Hanna Sikorska | Characteristics and use of the anti-cea antibody produced by the hybridoma having the atcc number hbl0029 |
CN101607985A (zh) * | 2008-12-24 | 2009-12-23 | 中国科学院生物物理研究所 | 抗人cea的单克隆抗体,包含其的组合物,及其用途 |
-
2013
- 2013-02-04 CN CN201310041303.3A patent/CN103173417B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1330545C (en) * | 1989-09-15 | 1994-07-05 | Hanna Sikorska | Characteristics and use of the anti-cea antibody produced by the hybridoma having the atcc number hbl0029 |
CN101607985A (zh) * | 2008-12-24 | 2009-12-23 | 中国科学院生物物理研究所 | 抗人cea的单克隆抗体,包含其的组合物,及其用途 |
Non-Patent Citations (4)
Title |
---|
CEA MAB的制备、纯化及其双抗夹心ELISA检测方法的初步建立;谢永华;《中国优秀硕士学位论文全文数据库》;20120315(第03期);E060-30 * |
Monoclonal antibodies to carcino-embryonic antigen;Jiti-Ghee Teh等;《Immunol. Cell Bioi.》;19900831;第68卷;263-268 * |
抗人癌胚抗原单克隆抗体的研制及其在免疫组化中的应用;吴萌 等;《河北省科学院学报》;20090331;第26卷(第1期);47-49 * |
抗癌胚抗原单克隆抗体的制备和初步应用;王玉金 等;《中国肿瘤》;20031231;第12卷(第12期);733-735 * |
Also Published As
Publication number | Publication date |
---|---|
CN103173417A (zh) | 2013-06-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102634486B (zh) | Gpc3单克隆抗体杂交瘤细胞株7d11及其制备方法和应用 | |
CN103923214B (zh) | 抗肝癌干细胞单克隆抗体及其应用 | |
CN105504049B (zh) | 宫颈癌相关的hpv e7蛋白单克隆抗体及其应用 | |
CN108467432A (zh) | 抗E-cadherin蛋白的单克隆抗体及其细胞株、制备方法和应用 | |
CN103173413A (zh) | 小鼠抗人β-Catenin单克隆抗体及分泌该单克隆抗体的杂交瘤细胞株 | |
CN101463344B (zh) | 抗人Her2单克隆抗体杂交瘤细胞系、单克隆抗体、试剂盒及其用途 | |
CN103880956B (zh) | 抗muc1单克隆抗体及其轻链和重链可变区 | |
CN105801691B (zh) | 一种hpv16e7单克隆抗体及其制备方法和应用 | |
CN103173417B (zh) | 小鼠抗人cea单克隆抗体及分泌该单克隆抗体的杂交瘤细胞株 | |
CN102634487B (zh) | Gpc3单克隆抗体杂交瘤细胞株8g6及其制备方法和应用 | |
CN103923212A (zh) | Ehd2抗体及其在制备乳腺癌免疫组化检测试剂中的应用 | |
CN104894074B (zh) | 分泌s100a9单克隆抗体的杂交瘤细胞株、单克隆抗体及其应用 | |
CN105646711A (zh) | 小鼠抗人ck8单克隆抗体及分泌该单克隆抗体的杂交瘤细胞株 | |
CN103173412B (zh) | 小鼠抗人cd20单克隆抗体及分泌该单克隆抗体的杂交瘤细胞株 | |
CN105646705A (zh) | 小鼠抗人gfap单克隆抗体及分泌该单克隆抗体的杂交瘤细胞株 | |
CN104610441B (zh) | 用于制备磷脂酰肌醇蛋白聚糖‑3(gpc3)单抗的人工半抗原、制备方法及获得的单克隆抗体 | |
CN103289962B (zh) | 小鼠抗人cd23单克隆抗体及分泌该单克隆抗体的杂交瘤细胞株 | |
CN103173416A (zh) | 小鼠抗人ck19单克隆抗体及分泌该单克隆抗体的杂交瘤细胞株 | |
CN102220285B (zh) | 流产嗜性衣原体外膜蛋白单克隆抗体及其应用 | |
CN108034638A (zh) | 小鼠抗人Desmin单克隆抗体及分泌该单克隆抗体的杂交瘤细胞株 | |
CN105017403B (zh) | 胰腺癌相关多肽dap44单克隆抗体的制备及其应用 | |
CN106754740A (zh) | 小鼠抗人mdr‑1单克隆抗体及分泌该单克隆抗体的杂交瘤细胞株 | |
CN102776154A (zh) | 小鼠抗人β-Tubulin单克隆抗体及分泌该单克隆抗体的杂交瘤细胞株 | |
CN103173414B (zh) | 小鼠抗人p504s单克隆抗体及分泌该单克隆抗体的杂交瘤细胞株 | |
CN103173415A (zh) | 小鼠抗人egfr单克隆抗体及分泌该单克隆抗体的杂交瘤细胞株 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: TIANJIN SUNGENE BIOTECH CO., LTD. Free format text: FORMER NAME: TIANJIN SUNGENE BIOTECHNOLOGY CO., LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: 300457, Tianjin Binhai New Area Tanggu economic and Technological Development Zone Fourth Avenue 80 days big science and Technology Park C5-106/311 Patentee after: TIANJIN SUNGENE BIOTECH Co.,Ltd. Address before: 300457, Tianjin Binhai New Area Tanggu economic and Technological Development Zone Fourth Avenue 80 days big science and Technology Park C5-106/311 Patentee before: TIANJIN SUNGENE BIOTECH Co.,Ltd. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Mouse anti-human CEA (Carcino-Embryonic Antigen) monoclonal antibody and hybridoma cell strain secreting same Effective date of registration: 20170508 Granted publication date: 20150422 Pledgee: Zheshang Bank, Limited by Share Ltd, Tianjin branch Pledgor: TIANJIN SUNGENE BIOTECH CO.,LTD. Registration number: 2017120000022 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: Patent of Tianjin Sanjian Biotechnology Co.,Ltd. The person in charge Document name: payment instructions |
|
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: Liu Chen Document name: Patent termination notice |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150422 |